SUNEKOS references stocked by ALLPARA for professional use, sourced direct and certified on every shipment.
SUNEKOS Inticare
Sunekos Inticare is an injectable medical device by Sunekos, developed by Professional Dietetics for the intimate area with specific therapeutic indications. It is suitable for qualified practitioners treating Vulvo-Vaginal Atrophy (VVA) on the labia minora, labia majora, vestibule, vaginal introitus and vaginal walls. Its patented HY6AA formula combines non-cross-linked low molecular weight hyaluronic acid with a cluster of six amino acids, designed to restructure the extracellular matrix of the mucosal lining and produce a long lasting physiological rehydration, and the product is intended for professional use. It comes as a pack of two 3 ml treatments to be reconstituted.
主なメリット: SUNEKOS Inticare
- CE-marked Class III medical device for the intimate area with specific therapeutic indications
- Indicated for the treatment of Vulvo-Vaginal Atrophy (VVA)
- Promotes the restoration of the physiological conditions of elasticity of the soft tissue
- Supports the regeneration of the soft tissue
- Restructures the extracellular matrix of the mucosal lining in the vulvo-vaginal area
- Produces a long lasting physiological rehydration
- Based on the patented HY6AA formula: non-cross-linked low molecular weight hyaluronic acid with six amino acids
- Can be used in combo treatment with CO2 laser, non-fractional radio frequency and carboxytherapy
- High tolerability in preliminary data from a multicentric clinical trial on 85 patients, with no adverse events recorded
適応と専門的な使用
主な適応
- Vulvo-Vaginal Atrophy (VVA)
- Loss of elasticity of the vulvo-vaginal soft tissue
- Degradation of the extracellular matrix of the vulvo-vaginal mucosal lining
- Reduced physiological hydration of the intimate area
専門的な使用
Sunekos Inticare is a Class III medical device for the intimate area, supplied for professional use only and administered by qualified medical practitioners trained in vulvo-vaginal injection technique. The product is supplied as a pack of two treatments to be reconstituted before use, each combining a 3 ml vial of non-cross-linked low molecular weight hyaluronic acid with a 100 mg bottle of the patented 6AA formula. The treating practitioner determines patient suitability, the areas treated, the injection plane, the dose per point and the session interval. Technique differs by area: the labia majora are treated sub-cutaneously with a fan technique using a 13 mm 30-32 G needle at 0.3 ml per point; the vestibule, introitus and vaginal walls are treated with micro-bolus injections using a 4 mm 30-32 G needle at about 0.03 ml per point, intra-mucosa at 2 mm depth for the introitus and vaginal walls. Aseptic technique applies throughout and any unused reconstituted solution is discarded.
施術部位
- Labia Minora
- Labia Majora
- Vestibule
- Vaginal Introitus
- Vaginal Walls
対象となる患者
Sunekos Inticare is intended for adult patients presenting with vulvo-vaginal atrophy, where restoration of mucosal elasticity and physiological hydration is the treatment goal. Suitability, the areas to be treated and the number of sessions are determined by the treating practitioner following clinical assessment. In preliminary data from a multicentric clinical trial, the treatment was evaluated on 85 patients with vulvo-vaginal atrophy using the Likert scale, showed high tolerability and recorded no adverse events.
作用の仕組み: SUNEKOS Inticare
Sunekos Inticare acts by promoting the restoration of the physiological conditions of elasticity and the regeneration of the soft tissue. The patented HY6AA formula combines non-cross-linked low molecular weight hyaluronic acid with a cluster of six amino acids, glycine, L-proline, L-lysine HCl, L-leucine, L-valine and L-alanine, in a specifically balanced solution. The combination is designed to restructure the extracellular matrix of the mucosal lining in the vulvo-vaginal area rather than to add volume, producing a long lasting physiological rehydration of the treated tissue.
Allparaで注文する理由
Allparaは、正規品で検証済みの SUNEKOS 製品を厳選されたサプライヤーから提供し、完全なロットトレーサビリティと専門家によるサポートを備えています。CE認証製品、EU倉庫からのEU全域への迅速な配送、競争力のある業務用価格で、クリニックと美容医療の専門家にサービスを提供しています。私たちが重視するのは患者様の安全、満足、そして結果です。安心してご利用いただけるよう、専任のアフターサポートをご用意しています。
よくある質問
What is Sunekos Inticare indicated for?
Sunekos Inticare is a Class III medical device for the intimate area, indicated for the treatment of Vulvo-Vaginal Atrophy (VVA).
Which areas can be treated with Sunekos Inticare?
The labia minora, labia majora, vestibule, vaginal introitus and vaginal walls. Injection technique and dose per point differ by area and are determined by the treating practitioner.
What does Sunekos Inticare contain?
Each treatment combines a 3 ml vial of non-cross-linked low molecular weight hyaluronic acid with a 100 mg bottle of the patented 6AA formula: glycine, L-proline, L-lysine HCl, L-leucine, L-valine and L-alanine, in a specifically balanced solution. The two components are reconstituted before use.
What is the Sunekos Inticare protocol?
The protocol is 3 injections at 21 day intervals. The practitioner sets the areas treated and the dose per point for each patient.
その他の製品: Professional Dietetics
Clinic alternatives
Pick up where you left off
SUNEKOS Inticare
Sunekos Inticare is an injectable medical device by Sunekos, developed by Professional Dietetics for the intimate area with specific therapeutic indications. It is suitable for qualified practitioners treating Vulvo-Vaginal Atrophy (VVA) on the labia minora, labia majora, vestibule, vaginal introitus and vaginal walls. Its patented HY6AA formula combines non-cross-linked low molecular weight hyaluronic acid with a cluster of six amino acids, designed to restructure the extracellular matrix of the mucosal lining and produce a long lasting physiological rehydration, and the product is intended for professional use. It comes as a pack of two 3 ml treatments to be reconstituted.
主なメリット: SUNEKOS Inticare
- CE-marked Class III medical device for the intimate area with specific therapeutic indications
- Indicated for the treatment of Vulvo-Vaginal Atrophy (VVA)
- Promotes the restoration of the physiological conditions of elasticity of the soft tissue
- Supports the regeneration of the soft tissue
- Restructures the extracellular matrix of the mucosal lining in the vulvo-vaginal area
- Produces a long lasting physiological rehydration
- Based on the patented HY6AA formula: non-cross-linked low molecular weight hyaluronic acid with six amino acids
- Can be used in combo treatment with CO2 laser, non-fractional radio frequency and carboxytherapy
- High tolerability in preliminary data from a multicentric clinical trial on 85 patients, with no adverse events recorded
適応と専門的な使用
主な適応
- Vulvo-Vaginal Atrophy (VVA)
- Loss of elasticity of the vulvo-vaginal soft tissue
- Degradation of the extracellular matrix of the vulvo-vaginal mucosal lining
- Reduced physiological hydration of the intimate area
専門的な使用
Sunekos Inticare is a Class III medical device for the intimate area, supplied for professional use only and administered by qualified medical practitioners trained in vulvo-vaginal injection technique. The product is supplied as a pack of two treatments to be reconstituted before use, each combining a 3 ml vial of non-cross-linked low molecular weight hyaluronic acid with a 100 mg bottle of the patented 6AA formula. The treating practitioner determines patient suitability, the areas treated, the injection plane, the dose per point and the session interval. Technique differs by area: the labia majora are treated sub-cutaneously with a fan technique using a 13 mm 30-32 G needle at 0.3 ml per point; the vestibule, introitus and vaginal walls are treated with micro-bolus injections using a 4 mm 30-32 G needle at about 0.03 ml per point, intra-mucosa at 2 mm depth for the introitus and vaginal walls. Aseptic technique applies throughout and any unused reconstituted solution is discarded.
施術部位
- Labia Minora
- Labia Majora
- Vestibule
- Vaginal Introitus
- Vaginal Walls
対象となる患者
Sunekos Inticare is intended for adult patients presenting with vulvo-vaginal atrophy, where restoration of mucosal elasticity and physiological hydration is the treatment goal. Suitability, the areas to be treated and the number of sessions are determined by the treating practitioner following clinical assessment. In preliminary data from a multicentric clinical trial, the treatment was evaluated on 85 patients with vulvo-vaginal atrophy using the Likert scale, showed high tolerability and recorded no adverse events.
作用の仕組み: SUNEKOS Inticare
Sunekos Inticare acts by promoting the restoration of the physiological conditions of elasticity and the regeneration of the soft tissue. The patented HY6AA formula combines non-cross-linked low molecular weight hyaluronic acid with a cluster of six amino acids, glycine, L-proline, L-lysine HCl, L-leucine, L-valine and L-alanine, in a specifically balanced solution. The combination is designed to restructure the extracellular matrix of the mucosal lining in the vulvo-vaginal area rather than to add volume, producing a long lasting physiological rehydration of the treated tissue.
Allparaで注文する理由
Allparaは、正規品で検証済みの SUNEKOS 製品を、完全なロットトレーサビリティ、CE認証在庫、EU全域への迅速な配送、専門的なアフターサポートとともに提供しています。
よくある質問
What is Sunekos Inticare indicated for?
Sunekos Inticare is a Class III medical device for the intimate area, indicated for the treatment of Vulvo-Vaginal Atrophy (VVA).
Which areas can be treated with Sunekos Inticare?
The labia minora, labia majora, vestibule, vaginal introitus and vaginal walls. Injection technique and dose per point differ by area and are determined by the treating practitioner.
What does Sunekos Inticare contain?
Each treatment combines a 3 ml vial of non-cross-linked low molecular weight hyaluronic acid with a 100 mg bottle of the patented 6AA formula: glycine, L-proline, L-lysine HCl, L-leucine, L-valine and L-alanine, in a specifically balanced solution. The two components are reconstituted before use.
What is the Sunekos Inticare protocol?
The protocol is 3 injections at 21 day intervals. The practitioner sets the areas treated and the dose per point for each patient.